Get the Stockscreener App
3.64
2.41%
-0.09
Rocket Pharmaceuticals Inc stock is traded at $3.64, with a volume of 7.39M.
It is down -2.41% in the last 24 hours and up +8.01% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.73
Open:
$3.77
24h Volume:
7.39M
Relative Volume:
1.45
Market Cap:
$392.77M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.3236
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+19.34%
1M Performance:
+8.01%
6M Performance:
-65.23%
1Y Performance:
-80.31%
1-Day Range:
$3.59
$3.98
1-Week Range:
$2.88
$4.10
52-Week Range:
$2.19
$22.01
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.64 | 326.95M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Using economic indicators to assess Rocket Pharmaceuticals Inc. Equity Warrant potentialJuly 2025 Analyst Calls & Verified Stock Trade Ideas - Newser
Rocket Pharma Surges 28.87% on FDA Trial Resumption Enters Top 500 Volume - AInvest
Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold - insights.citeline.com
Goldman Sachs reiterates Sell rating on Rocket Pharmaceuticals stock - Investing.com
Rocket Pharmaceuticals Skyrockets 26.12%—What’s Fueling This Biotech Breakout? - AInvest
Rocket Pharmaceuticals Surges 21% on FDA Green Light for Gene Therapy Trial - AInvest
Rocket Pharmaceuticals Stock (RCKT) Opinions on FDA Clinical Hold Lift - Quiver Quantitative
Rocket Pharmaceuticals Makes Major Advances in Gene Therapy - StocksToTrade
Rocket Pharmaceuticals rises after FDA lifts clinical hold on gene therapy trial - TradingView
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. - Barron's
US FDA lifts clinical hold on Rocket Pharmaceuticals’ gene therapy trial - whbl.com
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume - Reuters
Rocket Pharmaceuticals’ Strategic Vision: A Game Changer? - StocksToTrade
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday - Benzinga
Rocket Pharmaceuticals (NASDAQ:RCKT) Surges 25% as FDA Lifts Clinical Hold on Danon Disease Gene Therapy | RCKT Stock Price - paginasiete.bo
Why Is Rocket Pharmaceuticals Stock Rallying TodayRocket Pharmaceuticals (NASDAQ:RCKT) - Benzinga
Rocket Pharmaceuticals' RP-A501 Trial Resumes: A Catalyst for Re-Rating? - AInvest
Rocket Pharmaceuticals Soars 26.8% on FDA Trial Resumption - AInvest
Rocket Pharmaceuticals announces FDA has lifted the clinical hold on the pivotal phase 2 trial of RP-A501 for the treatment of Danon Disease - MarketScreener
Why Is Rocket Pharma Stock Up 15% Pre-Market Today? - Menafn
Rocket Pharma Shares Jump After FDA Lifts Clinical Hold on Danon Phase 2 Trial - MarketScreener
Rocket Pharmaceuticals stock soars after FDA lifts clinical hold - Investing.com
Rocket Pharmaceuticals (RCKT) Surges 16% as FDA Lifts Trial Hold - GuruFocus
Rocket Pharma rises as FDA lifts clinical hold on gene therapy trial - Seeking Alpha
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial - Reuters
Why Is Rocket Pharma Stock Up 25% Pre-Market Today? - Stocktwits
FDA Lifts Hold on Rocket’s Danon Disease Trial - TipRanks
Rocket Pharmaceuticals Soars 14.78% on FDA Decision Hopes - AInvest
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - inkl
Rocket Pharmaceuticals' Resumption of RP-A501 Trial: A Strategic Inflection Point for Gene Therapy in Cardiovascular Rare Diseases - AInvest
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease - Business Wire
How to build a custom watchlist for Rocket Pharmaceuticals Inc.2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
Using RSI to spot recovery in Rocket Pharmaceuticals Inc. Equity Warrant2025 Price Action Summary & AI Based Trade Execution Alerts - Newser
What does recent volatility data suggest for Rocket Pharmaceuticals Inc.2025 Trading Recap & Risk Controlled Swing Alerts - Newser
Visualizing Rocket Pharmaceuticals Inc. stock with heatmapsEarnings Trend Report & High Accuracy Trade Alerts - Newser
What moving averages say about Rocket Pharmaceuticals Inc.Bond Market & Weekly High Potential Stock Alerts - Newser
How to monitor Rocket Pharmaceuticals Inc. Equity Warrant with trend dashboards2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
Real time alert setup for Rocket Pharmaceuticals Inc. performanceJuly 2025 Trends & Safe Capital Growth Tips - Newser
Is Rocket Pharmaceuticals Inc. Equity Warrant building a consolidation baseTrade Risk Report & Free Real-Time Volume Trigger Notifications - Newser
How to read the order book for Rocket Pharmaceuticals Inc.Portfolio Value Summary & Weekly Chart Analysis and Trade Guides - Newser
Can Rocket Pharmaceuticals Inc. rally from current levelsJuly 2025 EndofMonth & Low Risk Entry Point Tips - Newser
Is Rocket Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 EndofMonth & Reliable Price Breakout Alerts - Newser
Real time breakdown of Rocket Pharmaceuticals Inc. Equity Warrant stock performanceGold Moves & Safe Capital Allocation Plans - Newser
Rocket Pharmaceuticals Inc. stock outlook for YEARPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Tools to assess Rocket Pharmaceuticals Inc.’s risk profile2025 Major Catalysts & High Conviction Trade Alerts - Newser
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Militello John | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
361 |
1,082 |
55,924 |
| Schwartz Jonathan David | See Remarks |
Aug 18 '25 |
Sale |
3.06 |
1,680 |
5,149 |
222,414 |
| Schwartz Jonathan David | See Remarks |
Aug 19 '25 |
Sale |
3.00 |
805 |
2,412 |
221,609 |
| Wilson Martin | General Counsel |
Aug 18 '25 |
Sale |
3.06 |
1,004 |
3,077 |
136,050 |
| Wilson Martin | General Counsel |
Aug 19 '25 |
Sale |
3.00 |
588 |
1,762 |
135,462 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):